S. Bell

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

C. Parker, H. Pandha, A. Protheroe, 2008 .

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.

B. Polisky, M. Templin, P. Harvie, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).

G. Jayson, G. Rustin, H. Gabra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

D. Collins, A. Padhani, D. Koh, 2015, The oncologist.

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

R. Plummer, A. Futreal, M. Uttenreuther-Fischer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG)

F. Lieberman, P. Wen, R. Strowd, 2021, Neuro-Oncology.